NASDAQ:HTBX - Heat Biologics Stock Price, Price Target & More

Heat Biologics trades on the NASDAQ under the ticker symbol "HTBX."

Heat Biologics shares reverse split before market open on Monday, January 22nd 2018. The 1-10 reverse split was announced on Friday, January 19th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 19th 2018. An investor that had 100 shares of Heat Biologics stock prior to the reverse split would have 10 shares after the split.

Heat Biologics (NASDAQ:HTBX) released its quarterly earnings data on Tuesday, May, 15th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.70) by $0.05. The biopharmaceutical company had revenue of $0.75 million for the quarter. Heat Biologics had a negative net margin of 543.30% and a negative return on equity of 182.19%. View Heat Biologics' Earnings History.

Heat Biologics is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for Heat Biologics.

2 equities research analysts have issued twelve-month price targets for Heat Biologics' stock. Their forecasts range from $22.50 to $22.50. On average, they expect Heat Biologics' share price to reach $22.50 in the next year. View Analyst Ratings for Heat Biologics.

Heat Biologics saw a increase in short interest in the month of May. As of May 15th, there was short interest totalling 830,219 shares, an increase of 41.0% from the April 30th total of 588,986 shares. Based on an average daily volume of 6,200,249 shares, the days-to-cover ratio is presently 0.1 days. Approximately 15.3% of the company's shares are sold short.

Some companies that are related to Heat Biologics include Emisphere Technologies (EMIS), Adamis Pharmaceuticals (ADMP), Teligent (TLGT), Acer Therapeutics (ACER), Zynerba Pharmaceuticals (ZYNE), Otonomy (OTIC), BioDelivery Sciences International (BDSI), Bellerophon Therapeutics (BLPH), Alpine Immune Sciences (ALPN), Protagonist Therapeutics (PTGX), ContraFect (CFRX), Axovant Sciences (AXON), Genprex (GNPX), Aptevo Therapeutics (APVO) and Chembio Diagnostics (CEMI).

News stories about HTBX stock have trended somewhat positive recently, Accern reports. Accern scores the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Heat Biologics earned a news impact score of 0.07 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 47.21 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Shares of HTBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of HTBX stock can currently be purchased for approximately $2.20.

Heat Biologics has a market capitalization of $36.52 million and generates $1.51 million in revenue each year. Heat Biologics employs 19 workers across the globe.

Heat Biologics' mailing address is 801 CAPITOLA DRIVE, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-240-7133 or via email at [email protected]